About the company
Regeneron Pharmaceuticals is a leading biotechnology company known for its groundbreaking discoveries, cutting-edge developments, and successful commercialization of innovative products. With a focus on tackling various diseases, Regeneron has made significant contributions in the fields of eye disease, cardiovascular disease, cancer, and inflammation. One of Regeneron's notable achievements is the development and marketing of Eylea. This remarkable drug has been approved for the treatment of wet age-related macular degeneration, as well as other eye diseases. By targeting specific proteins that contribute to these conditions, Eylea has revolutionized the treatment landscape for patients suffering from these debilitating disorders. In addition to Eylea, Regeneron has also brought Praluent to market, a groundbreaking medication that targets LDL cholesterol. By effectively reducing LDL cholesterol levels, Praluent offers an innovative approach to combating cardiovascular disease, one of the leading causes of morbidity and mortality worldwide. Regeneron's commitment to innovative therapies extends to the field of immunology, where the company's product Dupixent has made significant strides. Dupixent is a monoclonal antibody that targets specific inflammatory proteins, offering hope for patients with chronic inflammatory conditions such as asthma and atopic dermatitis. The introduction of Dupixent has provided a new pathway to managing these complex diseases and improving the quality of life for countless individuals. In the field of oncology, Regeneron's research has led to the development of Libtayo, an immunotherapy drug that has shown promise in the treatment of certain types of cancer. By harnessing the power of the immune system, Libtayo offers a new approach to fighting cancer, providing hope for patients in their battle against this devastating disease. Furthermore, Regeneron's collaboration with Sanofi has resulted in the development of Kevzara, a treatment for rheumatoid arthritis. By targeting specific inflammatory molecules involved in the progression of this disease, Kevzara offers patients a valuable therapeutic option and the potential to improve their quality of life. Regeneron's commitment to advancing medical science extends beyond its marketed products. The company is actively engaged in the development of monoclonal and bispecific antibodies, collaborating with Sanofi, as well as other partners and independently. These partnerships enable Regeneron to access diverse expertise and resources, fostering the discovery and development of novel therapies for various diseases. Additionally, Regeneron has formed strategic partnerships to bring new technologies to their pipeline. Collaborating with Alnylam, the company explores the potential of RNA interference (RNAi) technology, which has demonstrated remarkable potential for inhibiting disease-causing genes at the molecular level. This partnership empowers Regeneron to leverage the capabilities of RNAi in the development of innovative therapeutics. Furthermore, Regeneron's partnership with Intellia focuses on the utilization of CRISPR-based gene editing technology. This revolutionary gene-editing technique allows for precise modification of the genetic code, providing an exciting avenue for developing breakthrough therapies for a wide range of conditions. With its diverse portfolio of marketed products and robust pipeline of novel therapies, Regeneron Pharmaceuticals continues to push the boundaries of medical science. Through relentless innovation and strategic collaborations, Regeneron remains at the forefront of discovering and commercializing treatments that have the potential to revolutionize patient care in numerous disease areas.
Website: https://www.regeneron.com
Data updated: May 1, 2026
